News | November 14, 2022
Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
Subscribe To Our Newsletter & Stay Updated
